NEW YORK, June 18, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it will host a key opinion leader (KOL) call on digital therapeutics for the management of diabetes and other chronic conditions on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time.

The call will feature a presentation by KOL David Simmons, MD, who will discuss the importance of digital therapeutics as a complement to the current standard of care for the long term management and treatment of patients with diabetes and other chronic diseases. Dr. Simmons will be available to answer questions at the conclusion of the event.

The DarioHealth management team will also discuss its state-of-the-art software as a service (SaaS) technology platform that has been clinically demonstrated to improve long-term health outcomes while lowering costs. Dario offers a holistic, integrated service that combines a proprietary medical device, mobile app, and digital and human coaching that enables real-time data capture and drives therapeutic interventions.

Tuesday, June 23rd @ 10:30amETWebcast: Click Here to Register for the Webcast

David A. Simmons, MD, a highly regarded diabetologist with more than 40 years of diverse experience in the areas of diabetes, metabolism and cardiovascular disease as a researcher, professor, corporate executive and board member. He currently serves as Principal of Metabolic Management Consultants, LLC. Previously, Dr. Simmons served as Vice President, Chief Medical Officer and Board Member at Ascensia Diabetes Care where he provided senior leadership during the transition of the company from a division of Bayer into a stand-alone medical solutions company. His responsibility included Medical Affairs, Clinical Affairs, Regulatory Affairs and Quality Assurance. Before Ascensia, he served as Vice President and Chief Medical Officer of Bayer Diabetes Care from 2007 to 2015. Earlier in his corporate career, Dr. Simmons also directed clinical research teams at Pfizer, Inc. that were involved in the development of atorvastatin (Lipitor) and Exubera, as well as other components of Pfizer's cardiometabolic portfolio. From 1983 until 1999, Dr. Simmons served as Fellow, Assistant Professor and Associate Professor at the University of Pennsylvania School of Medicine. Dr Simmons is an associate of the American Diabetes Association and a past fellow of the College of Physicians of Philadelphia. His research has been published in many peer-reviewed journals, including Science, Diabetologia, Journal of Clinical Investigation, Diabetes Care, Diabetes Technology and Therapeutics, and Journal of Diabetes Science and Technology. He serves on the editorial review boards of Diabetes Technology and Therapeutics and Journal of Diabetes Science and Technology. He was the recipient of the Outstanding Achievement in Diabetes Service award from the Pennsylvania affiliate of the American Diabetes Association in 1995.Dr. Simmons received his medical degree from the University of Pennsylvania School of Medicine. He completed his internship and residency in internal medicine at Baylor Medical College in Houston and his fellowship in the Diabetes Division at the George S. Cox Research Institute, UPenn School of Medicine.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, for more information, visit http://dariohealth.com

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it states that its SaaS technology platform that has been clinically demonstrated to improve long-term health outcomes while lowering costs. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact: Claudia Levi Content & Communications Manager[emailprotected] +1-347-767-4220

Media Inquiries:Investor Relations Contact:Matthew Picciano[emailprotected]+1-646-889-1200

SOURCE DarioHealth Corp.

http://dariohealth.com/

Originally posted here:
Dario Health to Host Key Opinion Leader Call on Digital Therapeutics for the Management of Diabetes and Other Chronic Conditions - PRNewswire

Baltimore-based biopharmaceutical company Glyscend Therapeutics closed a $20.5 million financing round that will help to advance its treatment for Type 2 diabetes toward clinical trials next year.

The round was led by healthcare-focused investors Brandon Capital Partners and Sant Ventures. In 2019, the company also previously received seed funding from Breakout Labs, which is a fund in the Thiel Foundation of Paypal cofounder and investor Peter Thiel.

Glyscend will use the funding for product development, scaling up manufacturing, and proof-of-concept clinical trials that are slated to begin in Australia in 2021.

The company is developing an oral therapy that is designed to offer specific benefits of surgery, without the need for invasive procedures.

The technology we are developing was inspired by the remarkable efficacy of gastric bypass surgery in correcting the metabolic disorder associated with type 2 diabetes, said Dr. Ashish Nimgaonkar, CEO of Glyscend, in a statement. Our goal is to develop an oral medication that works locally in the gastrointestinal tract to provide the benefits of gastric bypass surgery while greatly reducing the potential risks and complications.

Founded in 2104, the company evolved from research that originated at the Johns Hopkins Center for Bioengineering Innovation and Design, which has served as a launch point for multiple startups, via collaboration between the labs of Nimgaonkar and Dr. Jay Pasricha. In this research, scientists were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation following certain types of weight loss surgery, Nimgaonkar said. In seeking to create non-absorbable drugs, the team tapped the expertise of medicinal polymer chemist Dr. Thomas Jozefiak, who is chief scientific officer.

It licensed technology from the university, and is now based at the FastForward 1812 innovation hub near Johns Hopkins Hospital in East Baltimore, which has become a biotech hub through offering access to coveted wet lab space in the city and proximity to other young companies.

Being located close to John Hopkins University has been vital for us grow by tapping into the deep scientific expertise roots, Nimgaonkar said. It also offers access to the wealth of knowledge from one of the countrys leading healthcare universities.

Additional materials science research and development is also conducted at a Lowell, Massachusetts, location of JLABS, which is Johnson & Johnsonsstartup incubator.

Along with the funding, entrepreneur and executive Dr. Karen Talmadge, who cofounded Medtronic-acquired medical device company Kyphonand is a 25-year member of the American Diabetes Association, joined the companys board.

Type 2 diabetes is a terrible disease whose personal and societal impact is both under-appreciated and deeply misunderstood, Talmadge said in a statement. I am honored to join Glyscends board to help fulfill the companys mission of providing life-changing benefits to patients with diabetes by reducing or eliminating the burden of disease.

See the original post here:
Glyscend Therapeutics raises $20.5M Series A to advance a new way of treating Type 2 diabetes - Technical.ly

Type 2 diabetes, like many health conditions, can be life-threatening if not correctly managed. The threat comes in the form of having high blood sugar levels which is worsened by the wrong types of food, drink and even cooking oils. What is the best cooking oil to use to help lower your blood sugar?

Diabetes.co.uksaid: Extra virgin olive oil reduces blood sugar and cholesterol more than other kinds of fats.

In a study conducted at Sapienza University in Romen, the health benefits associated with a traditional Mediterranean diet for people with diabetes was investigated.

The findings of the study were consistent with previous studies, which have linked extra virgin olive oil to higher levels of insulin, making it beneficial to people with type 2 diabetes.

More surprising were the reduced levels of low-density lipoprotein (LDL) or bad cholesterol, associated with the extra virgin olive oil meal.

In study with the US National Library of Medicine National Institutes of Health, the effect of daily consumption of extra virgin olive oil on blood glucose among diabetic patients was analysed.

The study noted: Saudi Arabia has the highest prevalence of type 2 diabetes mellitus among the modern nation states in the world.

In addition, the majority of Saudi diabetic patients do not have their blood glucose controlled.

Data suggests that diet, rich in olive oil and nuts, significantly reduces fasting plasma glucose and glycated haemoglobin.

Olive oil has been associated with weight reduction as well as improvements in lipid profile.

In another study with the US National Library of Medicine National Institutes of Health, olive oil use in the prevention and management of type 2 diabetes mellitus was analysed.

The study noted: Olive oil as food is composed mainly of fatty acids and bioactive compounds depending on the extraction method.

We conducted a meta-analysis to illustrate the impact of this food on type 2 diabetes by investigating the association between olive oil and risk of type 2 diabetes and the effect the oil intake has on the management of type 2 diabetes.

The study concluded that evidence from the intake of olive oil could be beneficial for the prevention and management of type 2 diabetes.

More:
Type 2 diabetes: Using this oil when cooking could help lower your blood sugar levels - Express

An immunotherapy, chimeric antigen receptor T-cell (CAR-T), has revolutionized certain types of cancer treatments. The two approved CAR-T therapies are Novartis Kymriah (tisagenlecleucel) and Gilead Sciences Yescarta (Axicabtagene ciloleucel). They are essentially living therapies. They are drawn from a patient, engineered in a lab to focus more closely on the specific cancer, and reinfused into the patient where the cells grow and attack the cancer cells.

New research out of the Memorial Sloan Kettering Cancer Center suggests the genetically engineered immune cells can be used to treat diseases of senescence, which could include fibrotic liver disease, atherosclerosis, and diabetes.

Cellular senescence is a kind of zombie state related to aging, where cells stop dividing and growing, but dont actually die. It is particularly associated with diseases of aging.

Senescence is a double-edge sword, said Scott Lowe, chair of the Cancer Biology and Genetics Program at the Sloan Kettering Institute and co-responding author on the study. Cells in this state play an important role in wound healing and cancer deterrence. But if they linger for too long, they can cause chronic inflammation, which itself is a cause of many diseases. Finding a way to safely eliminate these cells would be a major therapeutic breakthrough in the treatment of these diseases.

The research was published in the June 17 issue of the journal Nature.

The research team compared molecules on the surface of senescent cells to other types of cells. They identified a molecule called urokinase plasminogen activator receptor (uPAR) that was enriched on the senescent cells, but largely absent on other cells. They then designed CAR-T cells that recognized uPAR.

Evaluating these newly engineered cells on mouse models of senescence-related diseases, such as cancer and liver fibrosis, they found that CAR-T cells successfully eliminated senescent cells from two different mouse models of liver fibrosis. The CAR-T cells also improved survival in lung cancer mouse models when dosed with drugs that induced senescence in this type of cancer.

The researchers plan to continue studying uPAR-directed CAR-T cells in other senescence-associated diseases, such as atherosclerosis, diabetes, and osteoarthritis, with hopes of developing them for clinical use in humans.

This study demonstrates that T-cell engineering and CAR therapy can be effective beyond cancer immunotherapy, said Michel Sadelain, director of the Center for Cell Engineering at Sloan Kettering.

Lowe added, We think this approach has the potential to tackle a number of senescence-related diseases for which new treatments are badly needed.

Senescence has been a growing field in the last few years. South San Francisco-based Unity Biotechnology focuses on senescence to halt, slow or reverse age-associated diseases. The companys pipeline includes UBX0101, which is in Phase II trials for osteoarthritis and UBX1967 and UBX1325 for age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Other programs are studying idiopathic pulmonary fibrosis, liver and kidney diseases, and neurodegenerative and cognitive disorders.

On March 31, the company announced that it had completed enrollment in its UNITY Phase II trial of UBX0101 in moderate-to-severe osteoarthritis of the knee. It was evaluating 183 patients and expects to report results in the second half of 2020

Research that came out of Rockefeller University last year found that, unexpectedly, the neurons affected by Parkinsons disease may actually be senescent and that these undead neurons release molecules that shut down neighboring brain cells that lead to common Parkinsons symptoms.

Senescent cells occur throughout the body, but it is not usually seen in nerve cells in the brain. Neurons halt division once fully formed. But the research group found that dopamine neurons that regulate motivation, memory and movement by producing dopamine can become senescent.

Similarly, in 2018, researchers at the University of Texas Health Science Center at San Antonio found cellular senescence was linked to tau protein tangles associated with end-stage Alzheimers disease. Cellular senescence can be a survival strategy for cells under stress, but it can also cause cells to behave abnormally and secrete toxins that kill surrounding cells.

Visit link:
Can CAR-T Cells Be Used to Treat Diseases like Diabetes and Fibrosis? - BioSpace

The global Millimeter Wave Diabetes Treatment Devices market is segregated on the basis of Type as Under 50 GHz and Above 50 GHz. Based on Application the global Millimeter Wave Diabetes Treatment Devices market is segmented in Type 1 Diabetes and Type 2 Diabetes.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

The global Millimeter Wave Diabetes Treatment Devices market report scope includes detailed study covering underlying factors influencing the industry trends.

Browse Full Report: https://www.marketresearchengine.com/millimeter-wave-diabetes-treatment-devices-market

The global Millimeter Wave Diabetes Treatment Devices market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Millimeter Wave Diabetes Treatment Devices market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Zimmer MedizinSysteme, Smiths Group, Domer Laser, Hubei YJT Technology and others are among the major players in the global Millimeter Wave Diabetes Treatment Devices market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Millimeter Wave Diabetes Treatment Devices Market has been segmented as below:

Millimeter Wave Diabetes Treatment Devices Market, By Type

Millimeter Wave Diabetes Treatment Devices Market, By Application

Millimeter Wave Diabetes Treatment Devices Market, By Region

Millimeter Wave Diabetes Treatment Devices Market, By Company

The report covers:

Report Scope:

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Millimeter Wave Diabetes Treatment Devices market share. Major industry players with significant revenue share include Zimmer MedizinSysteme, Smiths Group, Domer Laser, Hubei YJT Technology, Application C10, Application B10, Application B8, Application B9, Application B10, Application C10, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/millimeter-wave-diabetes-treatment-devices-market

Table of Contents:

Other Related Market Research Reports:

Medical Ultrasound Knife Market 2019 Demand, Size, Growth Research Report by 2024 MRE Analysis

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

The rest is here:
Millimeter Wave Diabetes Treatment Devices Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By...

LONDON, ONTARIO - TheNewswire - June 18, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, highlights positive results from its submitted abstract entitled "Clinical Validation of the Implanted Pre-Vascularized Cell Pouch(TM) as a Viable, Safe Site for Diabetes Cell Therapy," selected for presentation at the American Diabetes Association's (ADA) 80th Scientific Sessions held virtually June 12-16, 2020.

"Sernova was honored that its abstract was selected under peer review to be presented at the prestigious ADA Scientific Sessions. The findings reported in diabetic patients, demonstrate that human donor islets transplanted into Sernova's Cell Pouch consistently demonstrate islet survival and the ability to produce the array of hormones required to treat diabetes," said Dr. Philip Toleikis, President and CEO of Sernova.

The following provides the background of our scientific presentation:

- Cellular transplantation therapy has the potential to treat severe, chronic diseases such as Type 1 Diabetes (T1D). The transplantation site and device approach are major factors influencing successful clinical outcomes;

- With new cell-based emerging technologies, there continues to be a need to find a safe, retrievable, biologically compatible device for cellular transplantation and we believe Sernova's Cell Pouch System may provide such a solution;

- The transplantation of insulin-producing islets is a cellular replacement therapy for severe T1D in patients who experience life-threatening severe hypoglycemia unawareness events;

- In this clinical indication, Sernova has conducted a physician sponsored first-in-human study in Canada and currently has an ongoing company-sponsored Phase I/II human clinical study at the University of Chicago. In both clinical studies, patients with T1D were implanted with both sentinel (small devices removed to assess cell survival) and larger therapeutic devices, anywhere between 1 to 6 months;

- After being placed on immunosuppression, islets were isolated from donor pancreata and transplanted into patients within the device chambers. When possible, a pre-transplant sample of islets was saved for comparison to post-explant Cell Pouch islets; and

- Cell Pouches were explanted from patients, anywhere between 14-90 days post-transplant. The Cell Pouches were prepared, and sections were stained and imaged, and then reviewed by an independent clinical pathologist to assess the transplanted tissue for micro-vessel formation and vascularization; the presence of islets with insulin, C-peptide, and other endocrine hormones (such as glucagon and somatostatin); and exocrine tissue (such as pancreatic ductal tissue).

The data presented clinically demonstrate that the vascularized Cell Pouch provides a consistently safe and biologically suitable, retrievable environment for the transplantation and survival of functional islets. Specific findings based on a detailed histopathological analysis of nine Sernova Cell Pouches explanted from patients with T1D diabetes include:

- Explanted Cell Pouches show abundant, viable, organized islet cells intimately associated with blood vessels within a natural collagen matrix following transplantation without obvious rejection or infection;

- 100% showed present or abundant blood vessels;

- 89% showed present or abundant insulin;

- 78% showed present or abundant endocrine cells;

- 100% showed present or abundant ductal tissue;

- Islet cells required to control diabetes within the Cell Pouches consistently express insulin and other endocrine hormones, such as glucagon, somatostatin, and C-peptide, when identified histologically;

- Pre-transplant islet samples that show strongly expressed insulin, as well as other endocrine markers, were similarly identified in the explanted Cell Pouches following transplant; and

- The amount of islet/exocrine tissue within pre-transplanted samples was similar to that found in the Cell Pouch following transplantation.

In summary, the transplanted samples, when explanted and examined, demonstrate healthy, surviving islets with multiple cell types within the islets capable of producing the hormones that control blood sugar levels when housed in the vascularized tissue matrix of the Cell Pouch. Exocrine ductal tissue, when transplanted, also survived. The findings demonstrate the pre-transplant samples are consistent with the histology observed upon explantation of the Cell Pouch at different time points. These clinical findings demonstrate that the Cell Pouch is a viable, safe site for diabetes cell therapy.

Dr. Toleikis said, "The positive results reported in patients in this diabetes indication, implanted with Sernova's Cell Pouch and transplanted with islets, continue to validate our Cell Pouch System cell therapy therapeutics approach. Within the emerging cell therapy field, Sernova, with its advancing cell therapies including locally immune protected stem cell-derived cells, continues to position itself as a leader in the development of a 'functional cure' for all patients with diabetes and other chronic diseases."

A recording of Sernova's ADA Scientific Session presentation is available at http://www.sernova.com/updates.

ABOUT SERNOVA'S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial at the University of Chicago to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova's clinical trial are incapable of producing c-peptide, a biomarker for insulin produced by islet cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, are transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regard to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients are then further followed for one year to assess longer-term safety and efficacy.

For more information on this clinical trial, please visit http://www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit http://www.pwitkowski.org/sernova.

ABOUT SERNOVA'S CELL POUCH SYSTEM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit http://www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp.

Tel: (519) 858-5126

dominic.gray@sernova.com

http://www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova's actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company's ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company's Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company's quarterly and annual filings available on http://www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Go here to read the rest:
Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions - TheNewswire.ca

Bone health among those with diabetes could be under threat as new research shows the condition increases the risk of fractures.

A study, carried out by the University of Sheffield, found that people who have either type 1 or type 2 diabetes are at a greater risk of suffering from a hip fracture, or a similar injury.

The risk is larger among those with type 1 diabetes than people with type 2 diabetes, although this largely depends on how long the person has had the condition, researchers said.

Lead researcher Dr Tatiane Vilaca, from the University of Sheffields Mellanby Centre for Bone Research, said: Diabetes can cause a number of well-known complications including kidney problems, loss of eyesight, problems with your feet and nerve damage. However, until now many people with diabetes and their doctors are unaware that they are also at greater risk of bone fractures.

We need to raise awareness about the greater risk people with diabetes face to help them to prevent fractures. For example, preventing falls can reduce their risk of fracture.

Fractures can be very serious, especially in older people. Hip fractures are the most severe as they cause such high disability. Around 76,000 people in the UK suffer a hip fracture every year and it is thought as many as 20 per cent of people will die within a year of the fracture. Many others dont fully regain mobility, and for many people it can cause a loss of independence.

Read more on this topic:

Professor Richard Eastell, Professor of Bone Metabolism and Director of the University of Sheffields Mellanby Centre for Bone Research, said the findings highlights the urgent need for healthcare professionals to focus more on bone health among those with diabetes.

He added: We hope that by raising awareness about the greater risk people with diabetes face, bone density and bone strength will become something that doctors assess routinely in patients with the condition in the same way they do currently for other well-known complications.

The research was a collaboration with the University of California and has been published in the Bone journal.

Dr Steven Cummings, from Sutter Health, California, said: Patients with diabetes and the doctors who care for them should be aware of the increased risk of fractures. Patients are encouraged to ask their doctors what to do about that risk, and doctors should assess the risk and consider treatment to reduce that risk.

Continued here:
People with diabetes at higher risk of bone fractures - Diabetes.co.uk